{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:07:07Z","timestamp":1793416027628,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2019.07.023","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T08:06:37Z","timestamp":1563523597000},"page":"5404-5413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model"],"prefix":"10.1016","volume":"37","author":[{"given":"E.M.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7378-8167","authenticated-orcid":false,"given":"S.D.","family":"Dowall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5315-3882","authenticated-orcid":false,"given":"F.J.","family":"Salguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Yeates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hewson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.07.023_b0005","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.3390\/v4102031","article-title":"Pathogenesis of Lassa fever","volume":"4","author":"Yun","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2019.07.023_b0010","unstructured":"WHO. Lassa fever outbreak contained but continual vigilance needed. 2018."},{"key":"10.1016\/j.vaccine.2019.07.023_b0015","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/bmj.311.7009.857","article-title":"Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ","volume":"311","author":"Fisher-Hoch","year":"1995","journal-title":"Br Med J"},{"issue":"6648","key":"10.1016\/j.vaccine.2019.07.023_b0020","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/bmj.297.6648.584","article-title":"A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy","volume":"297","author":"Price","year":"1988","journal-title":"BMJ: Br Med J"},{"key":"10.1016\/j.vaccine.2019.07.023_b0025","first-page":"25","article-title":"Mammalian reservoirs of arenaviruses","volume":"262","author":"Salazar-Bravo","year":"2002","journal-title":"Curr Top Microbiol Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2019.07.023_b0030","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4269\/ajtmh.1996.55.661","article-title":"Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea","volume":"55","author":"ter Meulen","year":"1996","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"10.1016\/j.vaccine.2019.07.023_b0035","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00705-015-2418-y","article-title":"Past, present and future of arenavirus taxonomy","volume":"160","author":"Radoshitzky","year":"2015","journal-title":"Arch Virol"},{"issue":"15","key":"10.1016\/j.vaccine.2019.07.023_b0040","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1128\/JVI.74.15.6992-7004.2000","article-title":"Genetic diverstiy amoung Lassa virus strains","volume":"74","author":"Bowen","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.07.023_b0045","unstructured":"Inovio First to Advance Lassa Fever Candidate Vaccine Into a Clinical Trial [Internet]. 201Available from: https:\/\/www.prnewswire.com\/news-releases\/inovio-first-to-advance-lassa-fever-candidate-vaccine-into-a-clinical-trial-300853937.html."},{"key":"10.1016\/j.vaccine.2019.07.023_b0050","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1743-422X-7-279","article-title":"Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever","volume":"7","author":"Branco","year":"2010","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2019.07.023_b0055","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.virol.2005.01.019","article-title":"Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein","volume":"335","author":"Rodriguez-Carreno","year":"2005","journal-title":"Virology"},{"issue":"41","key":"10.1016\/j.vaccine.2019.07.023_b0060","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1016\/j.vaccine.2008.07.057","article-title":"Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates","volume":"26","author":"Lukashevich","year":"2008","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2019.07.023_b0065","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.vaccine.2010.11.079","article-title":"Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs","volume":"29","author":"Jiang","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2019.07.023_b0070","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(87)90767-7","article-title":"Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guinea pigs against Lassa fever","volume":"25","author":"Clegg","year":"1987","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2019.07.023_b0075","first-page":"1","article-title":"Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. npj","volume":"3","author":"Hallam","year":"2018","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2019.07.023_b0080","unstructured":"WHO. Efficacy trials of Lassa Vaccines: endpoints, trial design, site selection\u201d WHO Workshop Final Report 2018. Available from: https:\/\/www.who.int\/blueprint\/what\/norms-standards\/LassaVxeval_Final_MeetingReport.pdf?ua=1."},{"key":"10.1016\/j.vaccine.2019.07.023_b0085","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0140-6736(89)91833-3","article-title":"Identification of Lassa fever virus infection with recombinant nucleocapsid protein antigen","volume":"334","author":"Lloyd","year":"1989","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.vaccine.2019.07.023_b0090","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1128\/JVI.74.15.6777-6783.2000","article-title":"Effective vaccine for Lassa fever","volume":"74","author":"Fisher-Hoch","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.07.023_b0095","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.virol.2003.12.013","article-title":"Old and new world arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by lassa-specific human CD4+ T-cell clones","volume":"321","author":"ter Meulen","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.07.023_b0100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1073\/pnas.86.1.317","article-title":"Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the lassa virus glycoprotein gene","volume":"86","author":"Fisher-Hoch","year":"1989","journal-title":"PNAS"},{"issue":"6","key":"10.1016\/j.vaccine.2019.07.023_b0105","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1371\/journal.pmed.0020183","article-title":"Development of a new vaccine for the prevention of Lassa fever","volume":"2","author":"Geisbert","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2019.07.023_b0110","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0042-6822(89)90525-4","article-title":"Protection of guinea pigs from Lassa fever by Vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus","volume":"171","author":"Morrison","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.07.023_b0115","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J General Virol"},{"key":"10.1016\/j.vaccine.2019.07.023_b0120","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","article-title":"Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence","volume":"72","author":"Meyer","year":"1991","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2019.07.023_b0125","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1016\/S0264-410X(01)00075-5","article-title":"Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques","volume":"19","author":"Stittelaar","year":"2001","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2019.07.023_b0130","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE","volume":"28","author":"von Krempelhuber","year":"2010","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2019.07.023_b0135","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1\/2a clinical trial","volume":"14","author":"Kreijtz","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"51","key":"10.1016\/j.vaccine.2019.07.023_b0140","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.1016\/j.vaccine.2008.09.016","article-title":"Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers","volume":"26","author":"Guimar\u00e3es-Walker","year":"2008","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.023_b0145","doi-asserted-by":"crossref","first-page":"e91516","DOI":"10.1371\/journal.pone.0091516","article-title":"A novel vaccine against Crimean-Congo haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model","volume":"9","author":"Buttigieg","year":"2014","journal-title":"PLoS ONE"},{"issue":"8195","key":"10.1016\/j.vaccine.2019.07.023_b0150","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0140-6736(80)90322-0","article-title":"Isolated case of Lassa fever in Zaria, Northern Nigeria","volume":"316","author":"Grundy","year":"1980","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.vaccine.2019.07.023_b0155","doi-asserted-by":"crossref","first-page":"12471","DOI":"10.1128\/JVI.78.22.12471-12479.2004","article-title":"Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4","volume":"78","author":"McCurdy","year":"2004","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.07.023_b0160","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jmoldx.2011.08.002","article-title":"RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues","volume":"14","author":"Wang","year":"2012","journal-title":"J Mole Diagn"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.023_b0165","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0300985816677153","article-title":"Temporal progression of lesions in guinea pigs infected with Lassa virus","volume":"54","author":"Bell","year":"2017","journal-title":"Vet Pathol"},{"key":"10.1016\/j.vaccine.2019.07.023_b0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever","author":"Abreu-Mota","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2019.07.023_b0175","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1001\/jama.1990.03450160063030","article-title":"Acute sensorineural deafness in Lassa fever","volume":"264","author":"Cummins","year":"1990","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.vaccine.2019.07.023_b0180","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1752-1947-3-36","article-title":"Sensorineural hearing loss in Lassa fever: two case reports","volume":"3","author":"Okokhere","year":"2009","journal-title":"J Med Case Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2019.07.023_b0185","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw198","article-title":"Imported case of Lassa fever in Sweden with encephalopathy and sensorineural hearing deficit","volume":"3","author":"Grahn","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2019.07.023_b0190","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00405-010-1370-4","article-title":"Early-onset sensorineural hearing loss in Lassa fever","volume":"268","author":"Ibekwe","year":"2011","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.023_b0195","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/019459989210600303","article-title":"Audiometric comparison of Lassa fever hearing loss and idiopathic sudden hearing loss: evidence for viral cause","volume":"106","author":"Liao","year":"1992","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.vaccine.2019.07.023_b0200","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1128\/JVI.02948-15","article-title":"Animal model of sensorineural hearing loss associated with Lassa virus infection.","volume":"90","author":"Yun","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.07.023_b0205","first-page":"523","article-title":"Comparative pathology of Lassa virus infection in monkeys, guinea-pigs and Mastomys natalensis","volume":"52","author":"Walker","year":"1975","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2019.07.023_b0210","doi-asserted-by":"crossref","unstructured":"Jahrling PB, Smith S, Hesse RA, B RJ. Pathogensis of Lassa virus infection in guinea pigs. Infection and Immunity. 1982; 37(2): pp. 771-778.","DOI":"10.1128\/iai.37.2.771-778.1982"},{"issue":"4","key":"10.1016\/j.vaccine.2019.07.023_b0215","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3201\/eid2104.141469","article-title":"Sequence variability and geographic distribution of Lassa virus, Sierra Leone","volume":"21","author":"Leski","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.vaccine.2019.07.023_b0220","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.vaccine.2013.03.021","article-title":"Recombinant MVA vaccines: dispelling the myths","volume":"31","author":"Cottingham","year":"2013","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2019.07.023_b0225","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-10-2082","article-title":"Vaccination of metastatic renal cancer patients with MVA- 5T4: A randomised, double-blind, placebo-controlled phase, III study","volume":"16","author":"Amato","year":"2010","journal-title":"J Clin Cancer Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19309144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19309144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:34:47Z","timestamp":1759401287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19309144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":45,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X19309144"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}